# Iza-bren PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/iza-bren

> The next catalyst for iza-bren, sponsored by BRISTOL MYERS SQUIBB CO (BMY), is its topline data readout, Mar to Jun 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | iza-bren |
| Codes | BMS-986507 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | [Urothelial Cancer](https://sec-api.dev/indications/urothelial-cancer), [Breast Neoplasms](https://sec-api.dev/indications/breast-neoplasms), [Non-Small Cell Lung Cancer](https://sec-api.dev/indications/non-small-cell-lung-cancer) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06926868 (A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06926868

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06926868 (A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06926868

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07100080 (Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07100080

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07100080 (Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07100080

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Urothelial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07106762 (Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01-26 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07106762

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Urothelial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07106762 (Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01-26 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07106762

## Same indication

- [ABBV-1480](https://sec-api.dev/pdufa/abbv-1480) (ABBV)
- [VERZENIO (abemaciclib)](https://sec-api.dev/pdufa/abemaciclib) (LLY)
- [Piqray (alpelisib)](https://sec-api.dev/pdufa/alpelisib) (NVS)
- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)
- [Inluriyo™ (imlunestrant)](https://sec-api.dev/pdufa/imlunestrant) (LLY)
- [Ivonescimab](https://sec-api.dev/pdufa/ivonescimab) (SMMT)
- [JDQ443](https://sec-api.dev/pdufa/jdq443) (NVS)
- [N-803 + pembrolizumab](https://sec-api.dev/pdufa/n-803-pembrolizumab) (IBRX)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Plinabulin](https://sec-api.dev/pdufa/plinabulin) (BYSI)
- [Rilvegostomig](https://sec-api.dev/pdufa/rilvegostomig) (AZN)
- [Sigvotatug vedotin](https://sec-api.dev/pdufa/sigvotatug-vedotin) (PFE)
- [Telisotuzumab adizutecan](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) (ABBV)
- [Tukysa (tucatinib)](https://sec-api.dev/pdufa/tucatinib) (PFE)
- [VS-7375](https://sec-api.dev/pdufa/vs-7375) (VSTM)
- [(z)-endoxifen](https://sec-api.dev/pdufa/z-endoxifen) (ATOS)

Calendar months: [March 2028](https://sec-api.dev/fda-calendar/2028-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/iza-bren.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Iza-bren PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/iza-bren

```bibtex
@misc{secapidev_pdufa_iza_bren_20261116,
  title        = {Iza-bren PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/iza-bren}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_iza_bren_20261116","title":"Iza-bren PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/iza-bren","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
